Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide [1]

Lancet

Volumn 350, Issue 9078, 1997, Pages 635-636

  Vila, Jorge ^a   Nugier, Fabienne ^b   Barguès, Gérard ^b   Vallet, Thierry ^b   Peyramond, Dominique ^b   Hamedi Sangsari, Farid ^b   Seigneurin, Jean Marie ^b  

^a AFAVIR Aguettant Fabre Virologie   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; HYDROXYUREA;

CASE REPORT; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; LETTER; LYMPH NODE; LYMPHOID TISSUE; PRIORITY JOURNAL; REBOUND; SERODIAGNOSIS;

EID: 0030771289     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)24035-3     Document Type: Article

References (4)

1. Vila J, Biron F, Nugier F, et al. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 1996; 348: 203-04.
2. Malley S, Grange JM, Hamedi-Sangsari F, Vila J. Synergistic anti-HIV-1 effect of hydroxarnate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994; 91: 11017-21.
3. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266: 801-05.
4. Pereson A, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387: 188-91.